Maratha Headlines

Spinal Muscular Atrophy Clinical Trials 2023, Pipeline Drugs and Companies Insight Report: Analysis of Drugs, MOA, ROA, and Recent Developments by DelveInsight

 Breaking News
  • No posts were found

Spinal Muscular Atrophy Clinical Trials 2023, Pipeline Drugs and Companies Insight Report: Analysis of Drugs, MOA, ROA, and Recent Developments by DelveInsight

January 12
22:37 2023
Spinal Muscular Atrophy Clinical Trials 2023, Pipeline Drugs and Companies Insight Report: Analysis of Drugs, MOA, ROA, and Recent Developments by DelveInsight
Spinal Muscular Atrophy Pipeline

Spinal Muscular Atrophy pipeline constitutes 10+ key companies continuously working towards developing 10+ Spinal Muscular Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

Spinal Muscular Atrophy Overview

Spinal Muscular Atrophy (SMA) is a group of inherited disorders characterized by a loss of certain nerve cells in the spinal cord called motor neurons or anterior horn cells. Motor neurons receive the nerve impulses transmitted from the brain to the spinal cord (brainstem) and, in turn, transmit the impulses to the muscle via the peripheral nerves. 

 

“Spinal Muscular Atrophy Pipeline Insight, 2023″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market. 

 

To know more in detail about Spinal Muscular Atrophy pipeline report offerings, click here: Spinal Muscular Atrophy Pipeline Insight

 

The Spinal Muscular Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Some of the key takeaways from the Spinal Muscular Atrophy Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Spinal Muscular Atrophy treatment therapies with a considerable amount of success over the years. Spinal Muscular Atrophy Key players such as – Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Genethon, Astellas Pharma, Hoffmann-La Roche, and others, are developing therapies for the Spinal Muscular Atrophy treatment 
  • Spinal Muscular Atrophy emerging therapies such as – ACTX-401, Apitegromab, and others are expected to have a significant impact on the Spinal Muscular Atrophy market in the coming years.  

 

To know in detail about the Spinal Muscular Atrophy clinical trials and recent FDA approvals for Spinal Muscular Atrophy drugs, click here: https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight

 

Spinal Muscular Atrophy Pipeline Therapeutics Assessment

  • Spinal Muscular Atrophy Assessment by Product Type
  • Spinal Muscular Atrophy By Stage and Product Type
  • Spinal Muscular Atrophy Assessment by Route of Administration
  • Spinal Muscular Atrophy By Stage and Route of Administration
  • Spinal Muscular Atrophy Assessment by Molecule Type
  • Spinal Muscular Atrophy by Stage and Molecule Type 

 

DelveInsight’s Spinal Muscular Atrophy Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration 

 

Emerging Spinal Muscular Atrophy Drugs Under Different Phases of Clinical Development Include: 

  • ACTX-401: Novartis
  • Apitegromab: Scholar Rock
  • GYM329: Roche
  • And Many Others

 

Get a Free Sample PDF Report to know more about Spinal Muscular Atrophy Pipeline Assessment- Spinal Muscular Atrophy Drugs and therapies

 

Spinal Muscular Atrophy Pipeline Analysis:

The Spinal Muscular Atrophy pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Spinal Muscular Atrophy treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment.
  • Spinal Muscular Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Spinal Muscular Atrophy product details are provided in the report. Download the Spinal Muscular Atrophy pipeline report to learn more about the emerging Spinal Muscular Atrophy therapies@ Spinal Muscular Atrophy Therapeutic Assessment

  

Scope of Spinal Muscular Atrophy Pipeline Drug Insight    

  • Coverage: Global
  • Key Spinal Muscular Atrophy Companies: Acurastem, Everfront Biotech Co., Ltd, Eledon Pharmaceuticals, AL-S Pharma, Novartis, Annexon Biosceinces, MediciNova, Treeway, Biogen, and others
  • Key Spinal Muscular Atrophy Therapies: AS-202, HK001, Tegoprubart, AP-101, BLZ945, ANX005, MN-166, TW001, BIIB067, and others
  • Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies
  • Spinal Muscular Atrophy Market Dynamics:  Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers 

 

Table of Contents

1

Spinal Muscular Atrophy Report Introduction

2

Spinal Muscular Atrophy Executive Summary

3

Spinal Muscular Atrophy Overview

4

Spinal Muscular Atrophy- Analytical Perspective In-depth Commercial Assessment

5

Spinal Muscular Atrophy Pipeline Therapeutics

6

Spinal Muscular Atrophy Late Stage Products (Phase II/III)

7

Spinal Muscular Atrophy Mid Stage Products (Phase II)

8

Spinal Muscular Atrophy Early Stage Products (Phase I)

9

Spinal Muscular Atrophy Preclinical Stage Products

10

Spinal Muscular Atrophy Therapeutics Assessment

11

Spinal Muscular Atrophy Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Spinal Muscular Atrophy Key Companies

14

Spinal Muscular Atrophy Key Products

15

Spinal Muscular Atrophy Unmet Needs

16 

Spinal Muscular Atrophy Market Drivers and Barriers

17

Spinal Muscular Atrophy Future Perspectives and Conclusion

18

Spinal Muscular Atrophy Analyst Views

19

Appendix

20

About DelveInsight

 

Trending Reports:

Age Related Vision Dysfunction Market

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting